首页> 外文期刊>Minimally invasive therapy and allied technologies: MITAT : official journal of the Society for Minimally Invasive Therapy >Excellence in non-small cell lung cancer staging by endobronchial-TBNA: Comparison with PET-CT and surgery
【24h】

Excellence in non-small cell lung cancer staging by endobronchial-TBNA: Comparison with PET-CT and surgery

机译:Endobronchial-tbna的非小细胞肺癌卓越症:与PET-CT和手术的比较

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To determine the correlation and/or discrepancies between positron emission tomography (PET-CT) findings, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and surgery in the staging of non-small cell lung carcinoma. Material and methods: Data were evaluated retrospectively from a prospective interventional endoscopy database. Positive results with EBUS-TBNA was the first end point and all cytology negatives were confirmed with mediastinoscopy/surgery. Results: Four hundred and eighty three patients were included and 1017 lymph nodes (LNs) were sampled in the study. One hundred and twenty eight LNs were excluded (positive with EBUS-TBNA). Four hundred and sixty five LN (52.3%) were found benign with EBUS-TBNA; however, only 15 of these were confirmed to be malignant by surgery (1.7%). The sensitivity, specificity, PPV, NPV and diagnostic accuracy of EBUS-TBNA were 96.5, 100, 100, 96.7 and 98.3%, respectively. The sensitivity, specificity, PPV, NPV and diagnostic accuracy of PET-CT for maximum standardized uptake value (SUVmax) 2.5 were 90.1, 29.2, 55.3, 75.4, 59.2%, respectively. A cut-off SUVmax of 5.2 was detected with 74.8% sensitivity, 84% specificity, 82.0% PPV, 77.5% NPV and 79.5% accuracy (area under the curve (AUC) of 0.818, 95% CI 0.791-0.843, p<.001). Conclusion: EBUS is a reliable, repeatable and safe technique with a high diagnostic accuracy and should be performed quickly to avoid superfluous time loss in the staging of lung cancer.
机译:目的:确定正电子发射断层扫描(PET-CT)调查结果,内核上的超声引导横向针吸附(EBUS-TBNA)和非小细胞肺癌分期的手术的相关性和/或差异。材料和方法:从预期介入内窥镜数据库回顾性评估数据。与EBUS-TBNA的阳性结果是第一终点,并用含有含有含有含有敏膜/手术证实的全细胞学底片。结果:在研究中包括四百八名患者,并在研究中取样1017个淋巴结(LNS)。一百二十八个LNS被排除在外(与ebus-tbna正面)。与EBUS-TBNA发现四百六十五LN(52.3%)良性;然而,只有15个被证实通过手术恶性(1.7%)。 EBUS-TBNA的敏感性,特异性,PPV,NPV和诊断准确性分别为96.5,100,100,96.7和98.3%。用于最大标准化摄取值(SUVMAX)2.5的PET-CT的敏感性,特异性,PPV,NPV和诊断准确性分别为90.1,29.2,55.3,75.4,59.2%。检测5.2的截止Suvmax,敏感性为74.8%,特异性为84%,PPV,77.5%NPV和79.5%的精度为0.818,95%CI 0.791-0.843,P <。 001)。结论:EBUS是一种可靠,可重复和安全的技术,具有高诊断准确性,应快速执行,以避免肺癌阶段中的多余时间损失。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号